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Abstract
Sarcomas are rare tumors with generally poor prognosis, for which current therapies have shown limited efficacy.
Histone deacetylase inhibitors (HDACi) are emerging anti-tumor agents; however, little is known about their effect in
sarcomas. By using established and patient-derived sarcoma cells with different subtypes, we showed that the pan-
HDACi, ITF2357, potently inhibited in vitro survival in a p53-independent manner. ITF2357-mediated cell death implied
the activation of mitochondrial apoptosis, as attested by induction of pro-apoptotic BH3-only proteins and a caspases-
dependent mechanism. ITF2357 also induced autophagy, which protected sarcoma cells from apoptotic cell death.
ITF2357 activated forkhead box (FOXO) 1 and 3a transcription factors and their downstream target genes, however,
silencing of both FOXO1 and 3a did not protect sarcoma cells against ITF2357-induced apoptosis and upregulated
FOXO4 and 6. Notably, ITF2357 synergized with Doxorubicin to induce cell death of established and patient-derived
sarcoma cells. Furthermore, combination treatment strongly impaired xenograft tumor growth in vivo, when
compared to single treatments, suggesting that combination of ITF2357 with Doxorubicin has the potential to
enhance sensitization in different preclinical models of sarcoma. Overall, our study highlights the therapeutic potential
of ITF2357, alone or in rational combination therapies, for bone and soft tissue sarcomas management.
Introduction
Soft tissue and bone sarcomas are rare and aggressive
tumors, including >50 histological subtypes with an
overall 5-year survival for all stages of about 55%1, 2.
Available therapeutic options for sarcoma patients with
advanced or metastatic tumors are anthracyclines (Dox-
orubicin or Epirubicin)-based chemotherapy regimens3–5.
Despite advances in the understanding of the molecular
basis of sarcomas, these are still insufficient for the
development of new-targeted strategies to potentially
improve the management of localized or advanced sar-
comas and the dismal prognosis of patients.
Inhibition of histone deacetylases (HDACs), enzymes
regulating chromatin topology and gene expression6 are
considered as new potential therapeutic agents able to
reverse aberrant histone acetylation and gene transcrip-
tion of cancer cells. HDAC inhibitors (HDACi) have been
reported as effective anti-cancer molecules alone or in
combination in preclinical7, 8 and clinical studies9–11. In
particular, several preclinical studies demonstrated that
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HDACi alone or in combination therapy constitute novel
therapeutics versus different sarcoma histotypes including
Ewing12, 13, epithelioid14, liposarcoma15, synovial and
rhabdomyosarcomas16–18, and osteosarcoma19–23. HDACi
activities have been mainly due to their effect on cell
growth and survival, on apoptosis or autophagy, or cancer
stem cells12,13,15, 24–27. On the basis of these preclinical
evidences, some HDACi against sarcomas have been
moving from phase I to phase II clinical trials alone or in
combination anthracyclines9,10, 28–30.
Here, we wanted to evaluate the effect of a new-
generation HDACi, ITF2357 (Givinostat®) in human sar-
coma cell lines. ITF2357 is a safe and tolerable pan-
HDACi with broad anti-inflammatory properties31, 32.
ITF2357 anti-tumoral activity has been reported in several
hematologic33–35 and solid tumor36, 37models, however,
little is known about ITF2357 activity in sarcomas. In the
present study, we investigated the molecular and func-
tional effects of ITF2357 in preclinical models of soft
tissue and bone sarcomas. We discovered that targeting
HDACs by ITF2357 induces a mitochondrial apoptosis in
human sarcoma cells. More importantly, ITF2357
enhances in vitro Doxorubicin (Doxo) cytotoxicity in both
established and patient-derived sarcoma cells. Further-
more, combination treatment strongly impaired xeno-
grafts tumor growth in vivo, when compared to single
treatments.
Results
ITF2357 reduces in vitro human sarcoma cell growth and
induces apoptosis by activating mitochondrial apoptotic
pathway
Firstly, we assessed the effect of ITF2357 on cell viability
of a panel of established human sarcoma cell lines
showing different p53 status, including osteosarcoma
(SaOS2, U2OS), liposarcoma (SW872), synovial sarcoma
(SW982), fibrosarcoma (HT1080), rhabdomyosarcoma
(A204), and leiomyosarcoma (SKLMS), that represent the
major histological entities of sarcoma family. As shown in
Fig. 1a and Fig. 1 suppl., ITF2357 strongly reduced sar-
coma cell viability regardless of p53 status, with IC50
values ranging from 3 µM in the p53 null line SaOS2, to
0.57–0.97 µM in p53-mutant lines (SW872, SKLMS) and
0.63–0.88 µM in wild-type (wt) p53 lines (U2OS, SW982,
HT1080, A204). To analyze ITF2357 effect on long-term
survival of sarcoma cells, we evaluated the clonogenic
growth of the representative HT1080 cell line upon
ITF2357 treatment. Of note, ITF2357 suppressed colony
growth in a dose-dependent manner (Fig. 1b). A 70%
reduction in clonogenic ability was observed after treat-
ment with 1 µM ITF2357. Furthermore, exposure to
ITF2357 markedly increased histone H3 and α-tubulin
protein acetylation in a dose-dependent manner in sar-
coma cell lines (Fig. 1c).
By using HT1080, SW872, and SaOS2 representative
cell lines, to study in depth molecular mechanisms of
ITF2357 we evaluated whether growth inhibition by
ITF2357 was due to apoptosis induction. Hence, we
assessed the apoptotic effects of ITF2357 by cytofluori-
metric analysis of AnnexinV/propidium iodide (PI)
staining. A dose-dependent increase in apoptotic cells was
observed after treatment with ITF2357 (Fig. 1d, e) in all
cell lines even though at different extent. Taken together,
these data indicate that ITF2357 treatment inhibited cell
proliferation in all sarcoma cell lines tested and that the
reduction in the cell viability was associated with induc-
tion of apoptosis independently of p53 status.
Focusing our attention on HT1080 cells, we explored
whether treatment with ITF2357 induced caspase-
dependent apoptosis by using the pan-caspase inhibitor,
zVAD-fmk (zVAD). As shown in Fig. 1f, ITF2357 trig-
gered the cleavage of poly(ADP ribose) polymerase
(PARP), a typical caspases substrate. We found that about
40% of ITF2357-treated cells were positive for active
caspase-3 staining, whereas <5% of zVAD-pretreated
cells, as well as, untreated cells were positive for caspase-3
staining (Fig. 1g). In agreement with these results, phar-
macological inhibition of caspases protected HT1080 cells
against ITF2357-induced loss of cell viability (Fig. 2a
suppl.). Next, we analyzed whether ITF2357-induced
apoptosis requires the mitochondrial apoptotic pathway.
To this aim, we used HT1080 cells overexpressing the
Fig. 1 ITF2357 affects survival of human sarcoma cells. a Analysis of cell viability by MTT assay in the indicated sarcoma cell lines treated for 72 h
with increasing concentrations of ITF2357. The results are reported as “viability of drug-treated cells/viability of control cells” × 100 and represent the
mean ± SD of three independent experiments performed in triplicate. b Colony formation of HT1080 cells treated for 24 h with increasing
concentrations of ITF2357. Representative images are shown. c Western blot analysis of acetylated histone H3 (Ac-H3), acetylated α-Tubulin (Ac-
Tubulin) in total cell lysates from the indicated cell lines treated with 0.1 and 0.5 μM ITF2357 for 24 h. d Representative experiment of apoptotic cells
evaluation by AnnexinV/PI staining in the indicated cell lines exposed to increasing concentration of ITF2357 for 72 h. e Quantification of apoptosis
by AnnexinV/PI staining in the indicated cell lines treated for 72 h with increasing concentrations of ITF2357. The results represent the mean ± SD of
three independent experiments. f Western blot analysis of cleaved form of PARP (PARP cl.) in total cell lysates from HT1080 cells treated with 1 and 5
μM ITF2357 for 72 h. c, f HSP72/73 expression was used as loading and transferring control. Western blots representative of two independent
experiments with similar results are shown. g Flow cytometric analysis of active caspase-3-PE staining in HT1080 cells untreated or treated for 72 h
with 1 μM ITF2357 alone or in combination with 50 μM pan-caspase inhibitor zVAD-fmk (zVAD). A representative experiment out of two is shown. a, e
p values were calculated between untreated and treated cells, *p < 0.01
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Fig. 2 ITF2357 activates mitochondrial apoptosis. a Western blot analysis of the indicated BH3-only pro-apoptotic proteins in total cell lysates
from the HT1080 cell line treated with 1 and 5 μM ITF2357 for 48 h. b–d Analysis of the indicated mRNA expression evaluated by qRT-PCR in HT1080
b, SW872 c, and SaOS2 d cell lines exposed to 1 and 5 μM ITF2357 for 48 h. Results are presented as the mean ± SEM of at least two independent
experiments. p values were calculated between untreated and treated cells, *p < 0.05. e Western blot analysis of p53 protein expression in total cell
lysates from the indicated cell lines treated for 48 h with ITF2357 (1 μM). As positive control of p53 induction, cells were exposed to Doxorubicin
(Doxo, 0.1 μM, 24 h). a, e HSP72/73 expression was used as loading and transferring control. Western blots representative of two independent
experiments with similar results are shown
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anti-apoptotic protein bcl-2. Interestingly, overexpression
of bcl-2 counteracted ITF2357-induced cell death, as
assessed by cell permeabilization (Fig. 2b suppl.) and
AnnexinV surface expression (Fig. 2c suppl.).
Next, we explored in HT1080 cells the expression levels
of pro-apoptotic members of the bcl-2 family via western
blot (Fig. 2a) and quantitative real-time PCR (qRT-PCR)
(Fig. 2b) analyses. Treatment with ITF2357 resulted in a
dose-dependent upregulation of Bim isoforms (BimEL,
BimL, and BimS). In addition, ITF2357 induced Noxa, Bax,
and Puma expression and triggered the cleavage of BH3-
only protein Bid (tBid), suggesting tBid recruitment at
mitochondria and its involvement in ITF2357-mediated
apoptosis. Notably, ITF2357 also transcriptionally upre-
gulated pro-apoptotic BH3-only proteins in SW872 cell
line, harboring p53 mutation (Fig. 2c). Of note, we found
that ITF2357 transcriptionally upregulated in a dose-
dependent manner pro-apoptotic BH3-only genes also in
p53 null SaOS2 cells (Fig. 2d), indicating that in our
experimental models, transcription of the pro-apoptotic
Fig. 3 ITF2357 induces a canonical autophagic process. a Representative images of autophagosomal structures by fluorescence microscopy in
HT1080 cells stably transfected with EGFP-LC3B vector (HT1080/EGFP-LC3) and treated with 1 and 5 μM ITF2357 for the indicated times. b
Quantification of cells positive for punctate autophagosomal structures treated as indicated in a. The results represent the mean ± SEM of three
independent experiments. c Western blot analysis of microtubule-associated protein 1 (LC3B-I/II) conversion and of p62/SQSTM1 protein expression
in total cell lysates from HT1080 cell line treated with increasing concentration of ITF2357 for 24 h. Western blots representative of two independent
experiments with similar results are shown. d Analysis of the indicated mRNA expression evaluated by qRT-PCR in HT1080 exposed to ITF2357 (1 and
5 μM for 24 h). Results are presented as the mean ± SEM of at least two independent experiments. p values were calculated between untreated and
treated cells, (*p < 0.05). e Analysis of cell death evaluated by PI staining in HT1080 cells exposed to ITF2357 for 48 h in absence or presence of
Chloroquine (CQ), a late stage autophagy inhibitor, *p < 0.05. The results represent the mean ± SD of three independent experiments
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BH3-only genes could involve factor(s) different from p53.
Accordingly, ITF2357 induced a decrease of mut-p53
protein levels in SW872 cells, while no accumulation of
p53 was observed after ITF2357 treatment of either
HT1080 cells, bearing wt-p53, or p53 null SaOS2 cells
(Fig. 2e).
Overall, these data indicate that ITF2357 induces
apoptosis in a caspase- and bcl-2-dependent manner,
through a p53-independent transcriptional mechanism.
ITF2357 induces autophagy in human sarcoma cells
Because it has been shown that ITF2357 induces
autophagy in other cancer models36, 37, we investigated
the effect of ITF2357 on autophagy also in sarcoma cell
lines. In HT1080 cells, the induction of autophagy by
ITF2357 was confirmed based on the increase of autop-
hagosomes formation, maturation, and degradation, as
well as the increase of lipidated form of LC3B (LC3B-II)
and the degradation of p62/SQTSM1, indicating that the
autophagic process is progressing to completion. In par-
ticular, we evaluated autophagy induction by analyzing
LC3B redistribution in HT1080 cells stably expressing the
EGFP-LC3B fusion protein (HT1080/EGFP-LC3). As
shown in Fig. 3a, b, a time- and dose-dependent
enhancement of punctate vesicular structures was
observed in ITF2357-treated cells when compared to
Fig. 4 ITF2357 induces FOXOs protein expression and transcriptional activity. a Analysis of FOXO1 and FOXO3 mRNA expression evaluated by
qRT-PCR in the indicated cell lines treated for 24 h with 1 and 5 μM ITF2357. b Representative images of immunofluorescence for FOXO1 and FOXO3
proteins in HT1080 cells after treatment with 1 μM ITF2357. c qRT-PCR analysis of the indicated mRNA expression in HT1080 cells treated for 24 h with
1 and 5 μM ITF2357. a, c Results are presented as the mean ± SEM of two independent experiments. p values were calculated between untreated and
treated cells, *p < 0.05
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untreated ones. To further assess the autophagic flux in
ITF2357-treated cells, we evaluated the autophagosome
maturation in HT1080 cells expressing mRFP-EGFP-LC3
reporter (HT1080/ptf-LC3). Notably, ITF2357 treatment
induced the autophagosome-lysosome fusion and com-
plete autophagosome maturation (Fig. 2d suppl.).
According with these results, we also found by western
blot analysis an increase of LC3B-II form and a decrease
of p62/SQTSM1 protein level upon treatment with
ITF2357 (Fig. 3c).
Next upon ITF2357 treatment, we evaluated the tran-
scriptional activation of ATG12, BECN1, and MAP1LC3B
genes, reported to be induced during the authophagic
process38. Interestingly, only ATG12 and MAP1LC3B
messenger RNA (mRNA) were substantially upregulated
in ITF2357-treated cells, while the expression level of
Fig. 5 Critical role of FOXOs protein in ITF2357-induced apoptosis. a Western blot analysis of FOXO1 and FOXO 3a protein expression in total
cell lysates from HT1080 cells after 48 h from trasfection with siRNA-mediated knockdown of FOXO1 and FOXO3a, alone (siFOXO1 and siFOXO3) and
in combination (siFOXO1/3) or with a control sequence (siScr). β-actin expression was used as loading and transferring control. Western blots
representative of two independent experiments with similar results are shown. b Flow cytometric analysis (left panel) and quantification (right panel)
of apoptotic cells by AnnexinV/PI staining HT1080 transfected with the indicated siRNAs (siScr, siFOXO1, siFOXO3a, and siFOXO1/3) and exposed to 1
µM ITF2357 for 48 h. The results represent the mean ± SD of three independent experiments. c qRT-PCR analysis of the indicated mRNA expression in
HT1080 transfected with the indicated siRNAs (siScr, siFOXO1, siFOXO3a, and siFOXO1/3) and exposed to 1 µM ITF2357 for 48 h. p values were
calculated between untreated and treated cells, *p < 0.05
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BECN1 mRNA was superimposable in untreated and
treated cells (Fig. 3d). We also evaluated the biological
outcome of autophagy inhibition upon ITF2357 treatment
by using chloroquine (CQ), an inhibitor of the lysosomal
pH gradient that blocks autophagy at late stage. As shown
in Fig. 3e, quantification of cell viability showed an
increased cell death when ITF2357 was combined with
CQ. Similarly, ITF2357 treatment induced autophagy also
in SW872 cells harboring mut-p53, as evidenced by ana-
lysis of LC3 puncta formation in SW872/EGFP-LC3B
cells (Fig. 2e suppl.). These results indicate that ITF2357
induces a canonical autophagic process both in wt- and
mut-p53 sarcoma cells and that ITF2357-induced autop-
hagy shows a cell survival mechanism.
Activation of Forkhead box (FOXOs) transcription factors
has a critical role in ITF2357-induced cell death
Several reports suggested a role for FOXO1 and
FOXO3a proteins in regulating apoptosis through the
expression of BH3-only target genes39. Thus, we tested
FOXOs expression in three representative sarcoma cell
lines exposed to ITF2357. As shown in Fig. 4a, FOXO1
and FOXO3a mRNA levels were increased in three dif-
ferent sarcoma cell lines treated with ITF2357. Next, we
analyzed FOXOs nuclear and cytosolic localization in
HT1080 cells upon ITF2357 exposure. As reported by
immunofluorescence analysis, a similar localization of
FOXO1 and FOXO3a was observed in HT1080 cells after
ITF2357 treatment (Fig. 4b). In particular, ITF2357-
treated cells showed a more evident nuclear localization
of FOXO3a in comparison to untreated ones. To further
confirm the transcriptional activity of FOXOs, we ana-
lyzed the transcription of CDKN1A/p21 and TP53PIN1,
two other well-known FOXO-target genes. As reported in
Fig. 4c, an increased expression of the two transcripts was
observed after ITF2357 treatment. These results suggest
that FOXOs might play a role in ITF2357-induced reg-
ulation of apoptosis. Thus, we proceeded to confirm the
relevance of FOXOs in ITF2357-mediated apoptosis by
testing the consequences of siRNA-mediated knockdown
of FOXO1 and FOXO3a, alone and in combination (Fig.
5a). Surprisingly, knockdown of FOXO1 or FOXO3a is
not associated with a decrease of apoptotic rates in
HT1080 cells treated with ITF2357. Notably, similar
results were obtained in HT1080 cells after simultaneous
knockdown of both FOXO1 and 3a (Fig. 5b). These
results were also corroborated by analysis of Bim
expression in HT1080 cells upon FOXOs silencing and
ITF2357 treatment. Indeed, after FOXOs silencing, Bim
expression was still upregulated in response to ITF2357
(Fig. 5c). Interestingly, we found that mRNA of other two
FOXO members, FOXO4 and FOXO6, were upregulated
in response to ITF2357 when FOXO1 and 3a were
downregulated. These results suggest that upregulation of
FOXO4 and 6 proteins might sustain ITF2357-mediated
apoptosis by upregulation of pro-apoptotic BH3-only
protein Bim (Fig. 5c).
ITF2357 sensitizes human sarcoma cells to doxorubicin
treatment both in vitro and in vivo
Based on these data, we decided to explore the effect of
ITF2357 in combination with conventional sarcoma
chemotherapy, such as Doxo, a topoisomerase II inhibitor
frequently used as first-line chemotherapeutic for sarco-
mas3. Sarcoma cell lines were exposed to ITF2357 or
Doxo alone or in combination (ratio 5:1) and their effect
on cell viability was evaluated. Next, combination index
(CI) was also calculated by conservative isobologram
analysis to evaluate the pharmacological interaction
between ITF2357 and Doxo. As shown by growth inhi-
bition curves (Fig. 6a), simultaneous treatment with
ITF2357 and Doxo resulted in a higher effect when
compared to single treatments, in all cell lines analyzed,
although to a different extent. In particular, in HT1080
cells, the combination of ITF2357 (0.5 μM) and Doxo (0.1
μM) caused a growth reduction of about 90%± 4.7, while
single treatments resulted in 50%± 3 and 63%± 10
growth reduction after treatment with ITF2357 or Doxo,
respectively. A similar effect was also observed in SW872
and SW982 cells. As reported in Table 1, ITF2357 acted
in a synergistic manner with Doxo in seven different cell
lines. Notably, a significant growth-inhibitory effect of
ITF2357 in vitro and a synergistic interaction with Doxo
was also evidenced in two-patient-derived sarcoma cell
lines (LSP1, 4052), while the effect of the two drugs was
additive in 3844B patient-derived sarcoma cell line (Table
1, Fig. 6b). We analyzed modulation of apoptosis follow-
ing single or combined treatment of two representative
cell lines, HT1080 and SW982. In agreement with cell
viability data, Annexin V staining shows that all the
assessed cell lines have the highest amount of early
apoptotic cells (Annexin V+/PI− cells) after combined
treatment when compared to the corresponding single
treatments (Fig. 6c).
The in vitro synergistic cytotoxic activities of Doxo and
ITF2357 observed in multiple sarcoma cell lines suggested
a therapeutic potential in vivo. To test this hypothesis, we
treated established SW982 soft tissue sarcoma40 xeno-
grafts for 4 weeks with vehicle, Doxo (2.2 mg/kg per
week), ITF2357 (100 mg/kg per day for 4 days), or com-
bination Doxo/ITF2357 (weekly Doxo followed by daily
ITF2357 for 4 days). As reported in Fig. 7a, treatment with
either Doxo or ITF2357 alone did not significantly affect
xenografts growth. On the contrary, the combined treat-
ment was significantly inhibitory and was highly tolerated,
as no significant weight loss, diet consumption, and pos-
tural and behavioral changes were observed. In vivo
experiments were also performed in HT1080 xenografts
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in which treatment with either Doxo or ITF2357 alone
slightly affects xenografts growth (about 15% of inhibi-
tion). On the contrary, the combined treatment reduces
HT1080 tumor growth of about 30% when compared to
control xenografts (data not shown). Accordingly, with
in vitro data, immunohistochemical analysis of SW982
tumor xenografts showed an increased percentage of
apoptotic cells in combination treatments when com-
pared to single ones (Fig. 7b, c). In particular, TUNEL-
positive staining nuclei revealed an apoptotic index of 5%
for control, 13.6% for Doxo, 13.4% for ITF2357, and 23.6%
for the combination. These results indicate that
ITF2357 sensitizes sarcoma from different histologic
subtypes and p53 mutational status to Doxo both in vitro
and in vivo.
Discussion
Novel therapies are urgent to improve the treatment of
sarcomas, a group of different tumors that show a poor
prognosis and a low curative outcome1, 4.
Using in vitro and in vivo sarcoma models, here we
demonstrate that the HDACi, ITF2357, decreases cell
viability, activates apoptosis, and increases the growth-
inhibitory efficacy of Doxo. We also show evidence about
the molecular mechanisms of action of ITF2357-mediated
cell death, which implied the activation of mitochondrial
Fig. 6 ITF2357 sensitizes human sarcoma cells to Doxorubicin treatment. a, b Analysis of cell viability by MTT assay in the indicated established
a and patient-derived b cell lines treated with ITF2357 and Doxorubicin (Doxo, drug ratio 5:1) alone or in combination. The results are reported as
“viability of drug-treated cells/viability of control cells” × 100 and represent the mean ± SD of three independent experiments performed in triplicate.
c Cytofluorimetric analysis of apoptotic cells in the indicated cell lines treated with ITF2357 (0.5 μM) and Doxo (0.1 μM) alone or in combination for 24,
48, and 72 h. The results are reported as mean ± SD of three independent experiments
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pathway of apoptosis, as attested by the increase of pro-
apoptotic BH3-only proteins, and both caspase- and bcl-
2-dependent cell death. BH3-only proteins are effectors of
mitochondrial apoptosis and are able to activate Bax and
Bak through direct or indirect mechanisms41. In agree-
ment with other groups demonstrating p53-independent
transcriptional regulation of some pro-apoptotic BH3-
only genes42, we found that ITF2357 transcriptionally
upregulated, in a dose-dependent manner, Bax, Puma,
Noxa, and Bim in cells harboring mutant or wt p53, thus
indicating a p53-independent mechanism.
The notion that activation of mitochondrial pathway
occurs upstream and before caspases activation is corro-
borated by results obtained in Bcl-2 overexpressing cells,
and by the use of zVAD, a broad-range caspase inhibitor:
both bcl-2 overexpression and caspases inhibition
strongly reduced apoptosis. Interestingly, we also found
that ITF2357 induces a canonical autophagic process, and
that inhibition of autophagy strongly increased apoptosis
induced by ITF2357, suggesting that in our models,
autophagy shows a pro-survival effect. Controversial
results have been reported about the effect of autophagy
on HDACi-mediated cell death, being observed both
cytoprotective and cytotoxic functions of autophagy43, 44.
We previously reported that ITF2357 in combination with
Pemetrexed caused a toxic form of autophagy that sub-
sequently activated a caspase-dependent apoptotic pro-
gram in lung cancer models37. In agreement with other
studies, we found that autophagy shows a prosurvival
effect. Among them, a recent study shows that FOXO1-
dependent pathways are implicated in HDACi-induced
autophagy26. FOXOs members, include transcription
factors with relevant role in gene regulation39. They act as
tumor suppressor genes and their alterations have been
reported in some human cancers39, including rhabdo-
myosarcoma and osteosarcoma45, 46. We reported that
HDAC inhibition by ITF2357, induced FOXO1/3 upre-
gulation, FOXO proteins nuclear accumulation, and
transcriptional activation of FOXO-target genes, such as
BH3-only proteins Puma, Noxa, and Bim, thus altering
the equlibrium between anti-apoptotic and pro-apoptotic
proteins belonging to bcl-2 family, which in turn culmi-
nates into mitochondrial alteration, caspases activation,
and DNA fragmentation. These data are in agreement
Table1 Response to ITF2357 and Doxorubicin in
combination of human sarcoma cells lines
CI values at
Cell line Subtype ED50 ED 75 ED90
HT1080 Fibrosarcoma 0.40 0.04 0.02
SW982 Synovial sarcoma 0.86 0.43 0.30
SW872 Liposarcoma 0.76 0.85 0.96
SaOS2 Osteosarcoma 0.73 0.85 1.04
U2OS Osteosarcoma 0.64 0.62 1.02
SKLMS Leiomyosarcoma 0.16 0.09 0.08
A204 Rabdomyosarcoma 0.52 0.51 0.98
3844b Osteosarcoma 1.08 1.00 0.95
4052 Condrosarcoma 0.98 0.80 0.76
LS1P Liposarcoma 0.86 0.83 0.84
CI combination index, ED effective dose
Fig. 7 ITF2357 reduces tumor growth and potentiates Doxorubicin effect in vivo. a In vivo response of SW982 xenograft to vehicle (daily),
Doxorubicin (Doxo, 2.2 mg/kg per week) or ITF2357 (100 mg/kg per day for 4 days) alone, or in combination (weekly Doxo followed by daily ITF2357
for 4 days). Treatments lasted 4 weeks. b Representative images of immunohistochemical detection of apoptosis by TUNEL assay of tumor xenografts
treated as reported in a
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with the well-established pro-apoptotic function of
FOXO1, through upregulation of Bim or Noxa genes
recently described in osteosarcoma46. Also the expression
of other downstream targets of FOXOs, including
CDKN1A/p21 and TP53PIN1, was found to be upregu-
lated in response to ITF2357 in sarcoma models.
Knockdown experiments were performed to deeper
investigate the role of FOXOs in cytotoxicity mediated by
ITF2357. Notably, reduction of both FOXO1 and 3a did
not inhibit the induction of Bim expression in response to
ITF2357, and consequently did not protect sarcoma cells
against ITF2357-induced apoptosis. Since we also
observed that in silenced cells, ITF2357 treatment upre-
gulated other two members of FOXO family, FOXO4 and
FOXO6, we might hypothesize that FOXO4 and FOXO6
upregulation might sustains ITF2357-mediated apoptosis
through upregulation of pro-apoptotic BH3-only protein
Bim. Overall, our results evidence similar FOXO-
dependent apoptotic mechanisms in response to
ITF2357 in sarcoma cells with wt or mutated p53 status.
We also studied the role of ITF2357 in combinatorial
regimes with Doxo, the current standard of systemic
therapy care for most subtypes of sarcoma. Overall our
results demonstrate that (1) co-treatment ITF2357/Doxo
strongly inhibits cell viability and determines a significant
increase in number of apoptotic cells when compared to
single treatments; (2) as evidenced by CI analysis, there is
a synergistic interaction of ITF2357 and Doxo to reduce
cell viability and induce apoptosis; (3) co-treatment
ITF2357/Doxo strongly reduces in vivo tumor growth,
whereas monotherapy with either agents exhibit no sig-
nificant anti-tumor effect; and (4) the clinical relevance of
co-treatment ITF2357/Doxo is also evidenced in primary
patient-derived sarcoma cells. These evidences demon-
strate the potency of this combination therapy in sarcoma
models and are in agreement with other sarcoma stu-
dies9,29, 47.
Taken together, our data indicate that ITF2357 may
represent an important potential therapeutic agent against
human sarcoma regardless of p53 status, and that the
pharmacological combination of ITF2357 with Doxo has
the potential to enhance sensitization in different pre-
clinical models of sarcoma. Based on these results, the
potential clinical value of ITF2357, over other HDACi
agents previously assessed in sarcoma, deserves further
studies in the future.
Materials and methods
Cell culture and chemicals
Established osteosarcoma (SaOS2, U2OS), liposarcoma
(SW872), synovial sarcoma (SW982), rabdomyosarcoma
(A204), leiomyosarcoma (SKLMS), and fibrosarcoma
(HT1080) cell lines were originally purchased from ATCC
(Manassas, VA). Patient-derived osteosarcoma (3844B),
liposarcoma (LS1P), and condrosarcoma (4052) cells were
obtained from Dr Baldini (Istituto Ortopedico Rizzoli,
Bologna, Italy). EGFP-LC3B, ptf-LC3, and GFP-bcl-2
stable clones, obtained as previously described48, were
cultured in the presence of geneticin (800 μg/ml, Sigma-
Aldrich, St. Louis, MO). Cells were routinely tested for
mycoplasm presence.
ITF2357 (diethyl-[6-(4-hydroxycarbamoyl-phenyl car-
bamoyloxymethyl)-naphthalen-2-yl methyl]-ammonium
chloride monohydrate) was provided by Italfarmaco
(patent WO 97/43251, US 6034096, Milan, Italy). Dox-
orubicin (Doxo) was obtained from Sigma-Aldrich. Pan-
caspase inhibitor zVAD-fmk (zVAD, 50 μM, Sigma-
Aldrich) and chloroquine diphosphate (CQ, 25 μM,
Sigma-Aldrich) were dissolved in DMSO and water,
respectively.
Analysis of cell viability and apoptosis
The effect of ITF2357 and Doxo on in vitro cell pro-
liferation was assessed following manufacturer’s protocol
by measuring 3-[4,5-dimethylthiazol-2-yl]-2,5-diphe-
nyltetrazolium bromide inner salt (MTT, Sigma-Aldrich)
dye absorbance. The viability was calculated for each
concentration of drugs used as “optical density (OD) of
treated cells/OD of control cells× 100.” By using Calcu-
syn software, we calculated the concentration of drug that
reduces 50% of cell viability (IC50). According to pilot
experiments, the DMSO concentration (0.05%) used for
the experiments did not affect the proliferation of sar-
coma cell lines (data not shown). Caspase-3 activation and
the presence of apoptotic cells were evaluated in
untreated or treated cells staining using active caspase 3-
PE antibody (cat. 559565, BD Bioscience, San Jose, CA)
and with Annexin V-FITC or AnnexinV-APC and PI
staining. Cytofluorimetric analysis was performed by BD
C6 Accuri as previously reported37.
Analysis of autophagy
LC3B puncta formation (autophagosomal structures) in
EGFP-LC3B-expressing cells, and distribuition/alteration
of fluorescent signals (autophagosome maturation) in
mRFP-GFP-LC3B-expressing cells were detected by
fluorescence microscopy after grown of cells on glass
coverslips and fixation formaldehyde (2%, 10 min, room
temperature)38.
Western blot and immunofluorescence analyses
Western blot and immunofluorescence analyses were
performed as previously described37, 48 using the follow-
ing antibodies: H3 acetylated histone (cat. 06-599),
FOXO3 (cat. 04-1007) (Millipore, Billerica, MA), p62/
SQSTM1 (cat. sc-28369), p53 (cat. sc-126), Bax (cat. sc-
493), Noxa (cat. sc-30209) (Santa Cruz, Biotechnology,
Santa Cruz, CA), HSP72/73 (cat. Hsp-01, Calbiochem,
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San Diego, CA), acetyl-α-tubulin (cat. T7451), Puma (cat.
PRS3041)(Sigma-Aldrich), LC3B (cat. 2775S), FOXO1
(cat. 2880) and BID (cat. 20025), Bim (cat. 2819) (Cell
Signaling, Danvers, MA). Goat anti-mouse IgG and goat
anti-rabbit IgG conjugated to horseradish peroxidase were
used as secondary antibodies. Enhanced chemilumines-
cence was used for detection (Amersham Bioscience,
Freiburg, Germany). Representative blots of at least two
independent experiments are shown.
Assessment of synergism between ITF2357 and Doxo
Effects of drugs combination were evaluated using the
CI equation through CalcuSyn software (Biosoft, Cam-
bridge, UK). Synergism CI <0.9, additivity 0.9<CI< 1.1,
antagonism CI> 1.1.
Quantitative RT-PCR analysis
Quantitative real-time PCR analysis was performed to
evaluate gene expression, as previously reported37. The
following primers were used: human Puma forward: 5′-
AAGTCAGGACTTGCAGGCGCG-3′; human Puma
reverse: 5′-TGGGTCCCAGTCCGTGTGTGT-3′; human
Bax forward: 5′-TCCCGGCTCTCTGATCCCCG-3′;
human Bax reverse: 5′-GGCTAGGGGAACGCTA-
TATGC-3′; human Noxa forward: 5′-CGCTGAC-
GACGTCCCAGCGTTT-3′; human Noxa reverse: 5′-
CGAAGACGGCGTTAT-3′; human Bim forward: 5′-
CAGAGATATGGATCGCCCAAG-3′; human Bim
reverse: 5′-TGCGTCTGCTACAGTGGTTCTT-3′;
human MAP1LC3B forward: 5′-
TGGCCCAACCTGTCTGTACTTC-3′; human
MAP1LC3B reverse: 5′-AAAAGTACCAGCCGCATG-
GAG-3′; human ATG12 forward: 5′-GCA-
GAAAAGGTTAGGCGTTTTG-3′; human ATG12
reverse: 5′-ATGTGCTTGCTCTCCTGGCTA-3′; human
BECN1 forward: 5′-AGGAACTCACAGCTCCATTAC-
3′; human BECN1 reverse: 5′-AATGGCTCCTCTCCT-
GAGTT-3′; human FOXO1 forward: 5′-AACCTGG-
CATTACAGTTGGCC-3′; human FOXO1 reverse: 5′-
AAATGCAGGAGGCATGACTACG-3′; human
FOXO3a forward: 5′-TGCGTGCCCTACTTCAAGGAT-
3′; human FOXO3a reverse: 5′-ACCCGCATGAATC-
GACTATGC-3′; human TP53PIN1 forward: 5′-
GAGGTTGTCACCAACGCACGT-3′; human TP53PIN1
reverse: 5′-TGAGGGAGAGATCCACCTCTG-3′; human
CDKN1A forward: 5′-CCTGGCACCT-
CACCTGCTCTGCTG-3′; human CDKN1A reverse: 5′-
GCAGAAGATGTAGAGCGGGCCTTTG-3′; human
FOXO4 forward: 5′ACTGTGGCAGGCTTCACTGAAC-
3′; human FOXO4 reverse: 5′TCTAGGTCTAT-
GATCGCGGCA-3′; human FOXO6 forward: 5′TCTAC-
GACTGGATGGTCCGT-3′; human FOXO6 reverse: 5′-
GGGTCTTCCCTGTCTTTCCG-3′; human GAPDH
forward: 5′-TCCCTGAGCTGAACGGGAAG-3′; human
GAPDH reverse: 5′-GGAGGAGTGGGTGTCGCTGT-3′;
human actin: forward: 5′-ATTGCCGACAGGATGCA-
GAA-3′; human actin reverse: 5′- GCTGATCCA-
CATCTGCTGGAA-3′.
Each sample was run in triplicate and normalized to
GAPDH or actin mRNA to evaluate relative expression.
The 2−ΔΔCt method was used to evaluate fold change in
gene expression levels, expressed in unit less values.
In vivo experiments
Procedures relative to animal use and care were
authorized and certified by Italian Minister of Health
(decree no. 67/97A, protocol 2560/97, Rome Health Ser-
vice Unit). Regina Elena National Cancer Institute and
animal care Unit approved all the procedures involving
animals (species, quality and number of animals, dis-
comfort/distress/pain of animals, anesthesia and killing).
SW982 of 5× 106 or HT1080 cells were intramuscularly
injected into immunodeficient athymic mice (6–8 week-
old female). Four groups of animals with similar tumor
volume were created when the tumors reach the palp-
ability. The following treatments administered for
4 weeks: (1) daily vehicle administration, (2) weekly
intraperitoneal treatment with Doxo (2.2 mg/kg), (3) daily
oral administration with ITF2357 (100 mg/kg) for 4 days,
and (4) sequential Doxo/ITF2357 treatment (weekly Doxo
followed by daily ITF2357 for 4 days). Ten animals
composed each group. Tumor volume (mm3) was daily
calculated to evaluate the effect of different treatments on
in vivo tumor growth. Animals were also daily monitored
for food consumption, body weight, and behavior.
The experiments were repeated twice. At the end of
treatment, tumors were excised, fixed in formalin,
embedded in paraffin, and stained with hematoxylin and
eosin. Tumor inhibition rate (%) was calculated as follows:
(mean tumor volume of control group−mean tumor
volume of treated group)/mean tumor volume of control
group× 100%. The non-parametric Mann–Whitney test
was employed to evaluate differences between the groups.
Differences were statistically significant when p< 0.05.
TUNEL assay (In Situ Cell Death Detection Kit, POD,
Roche) was used to detect apoptosis in tumor sections
according to the manufacturer’s instructions. Frozen
sections of 5 μm (3 for each tumor) were analyzed by light
microscopy and apoptotic cells were counted in four high-
power fields (×400 magnification).
Statistical analysis
All experiments were repeated at least two times. Cell
viability, apoptosis, and mRNA levels were expressed as
means± SD or means± SEM, and significances were
analyzed with the t test. All data were included in the
analyses. Based on variation shown in our previous
results, we determined the sample sizes by using power
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analysis37. Immunofluorescence and TUNEL analyses
were performed by two investigators in blinded and
independent manner.
Acknowledgements
We thank Dr. Adele Petricca for manuscript preparation. Supported by Grants
from Italian Association for Cancer Research (DDB IG 18560, NB IG 11426) and
IRE Translational Sarcoma Group (881/2015). M.G.T. is recipient of a fellowship
from FIRC.
Author details
1Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena
National Cancer Institute, Rome, Italy. 2Pathology Unit, IRCCS Regina Elena
National Cancer Institute, Rome, Italy. 3Cellular Networks and Molecular
Therapeutic Targets Unit, IRCCS Regina Elena National Cancer Institute, Rome,
Italy. 4Medical Oncology, IRCCS Regina Elena National Cancer Institute, Rome,
Italy. 5Orthopaedic Pathophysiology and Regenerative Medicine Unit, Istituto
Ortopedico Rizzoli, Bologna, Italy. 6Department of Biomedical and Neuromotor
Sciences, University of Bologna, Bologna, Italy. 7Oncological Orthopedics, IRCCS
Regina Elena National Cancer Institute, Rome, Italy. 8Institute of Molecular
Biology and Pathology, National Research Council, Rome, Italy
Author contributions
M.D.M., M.D., M.G.T., B.A., and C.M. performed the experiments; D.D.B., M.M., V.F.,
and R.B. edited the manuscript; R.F. and N.B. provided the cell lines; S.B., M.D.M.,
and M.D. analyzed the data; D.T. conceived, designed, performed the
experiments, and wrote the manuscript; D.D.B. supervised the study and wrote
and edited the manuscript; all authors read and approved the final manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Supplementary Information accompanies this paper at (https://doi.org/
10.1038/s41389-018-0026-x).
Received: 16 May 2017 Revised: 26 September 2017 Accepted: 9 November
2017
References
1. HaDuong, J. H., Martin, A. A., Skapek, S. X. & Mascarenhas, L. Sarcomas. Pediatr.
Clin. North Am. 62, 179–200 (2015).
2. Zahm, S. H. & Fraumeni, J. F. Jr The epidemiology of soft tissue sarcoma. Semin.
Oncol. 24, 504–514 (1997).
3. Walczak, B. E. & Irwin, R. B. Sarcoma chemotherapy. J. Am. Acad. Orthop. Surg.
21, 480–491 (2013).
4. Riedel, R. F. Systemic therapy for advanced soft tissue sarcomas: highlighting
novel therapies and treatment approaches. Cancer 118, 1474–1485 (2012).
5. Le Cesne, A. et al. Doxorubicin-based adjuvant chemotherapy in soft tissue
sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann.
Oncol. 25, 2425–2432 (2014).
6. Di Marcotullio, L., Canettieri, G., Infante, P., Greco, A. & Gulino, A. Protected from
the inside: endogenous histone deacetylase inhibitors and the road to cancer.
Biochim. Biophys. Acta 1815, 241–252 (2011).
7. Lane, A. A. & Chabner, B. A. Histone deacetylase inhibitors in cancer therapy. J.
Clin. Oncol. 27, 5459–5468 (2009).
8. Tan, J., Cang, S., Ma, Y., Petrillo, R. L. & Liu, D. Novel histone deacetylase
inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol. 3, 5 (2010).
9. Choy, E. et al. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor,
in combination with doxorubicin in patients with metastatic sarcoma. Cancer
121, 1223–1230 (2015).
10. Chu, Q. S. et al. A phase II study of SB939, a novel pan-histone deacetylase
inhibitor, in patients with translocation-associated recurrent/metastatic
sarcomas-NCIC-CTG IND 200†. Ann. Oncol. 26, 973–981 (2015).
11. Thomas, S. et al. A phase I trial of panobinostat and epirubicin in solid tumors
with a dose expansion in patients with sarcoma. Ann. Oncol. 27, 947–952
(2016).
12. Kayarthodi, S. et al. Anti-epileptic drug targets ewing sarcoma. J. Pharm. Sci.
Pharmacol. 1, 87–100 (2014).
13. Sampson V. B. et al. Vorinostat enhances cytotoxicity of SN-38 and temozo-
lomide in ewing sarcoma cells and activates STAT3/AKT/MAPK pathways. PLoS
ONE 10, e0142704 (2015).
14. Lopez, G. et al. HDAC inhibition for the treatment of epithelioid sarcoma:
novel cross talk between epigenetic components. Mol. Cancer Res. 14, 35–43
(2016).
15. Ou, W. B. et al. HDACi inhibits liposarcoma via targeting of the MDM2-p53
signaling axis and PTEN, irrespective of p53 mutational status. Oncotarget 6,
10510–10520 (2015).
16. Ma, L. et al. SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma
growth. Cell Death Dis. 5, e1483 (2014).
17. Laporte, A. N. et al. HDAC and proteasome inhibitors synergize to activate pro-
apoptotic factors in synovial sarcoma. PLoS ONE 12, e0169407 (2017).
18. Su, L., Cheng, H., Sampaio, A. V., Nielsen, T. O. & Underhill, T. M. EGR1 reacti-
vation by histone deacetylase inhibitors promotes synovial sarcoma cell death
through the PTEN tumor suppressor. Oncogene 29, 4352–4361 (2010).
19. Capobianco, E. et al. Separate and combined effects of DNMT and HDAC
inhibitors in treating human multi-drug resistant osteosarcoma HosDXR150
cell line. PLoS ONE 9, e95596 (2014).
20. Murahari, S. et al Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42
mediated apoptosis. BMC Cancer 17, 67 (2017).
21. Pettke, A. et al. Suberanilohydroxamic acid (vorinostat) synergistically enhances
the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell lines.
Anticancer Drugs 27, 1001–1010 (2016).
22. Thayanithy, V. et al. Combinatorial treatment of DNA and chromatin-
modifying drugs cause cell death in human and canine osteosarcoma cell
lines. PLoS ONE 7, e43720 (2012).
23. Blattmann, C. et al. Histone deacetylase inhibition sensitizes osteosarcoma to
heavy ion radiotherapy. Radiat. Oncol. 10, 146 (2015).
24. Luo, J., Su, F., Chen, D., Shiloh, A. & Gu, W. Deacetylation of p53 modulates its
effect on cell growth and apoptosis. Nature 408, 377–381 (2000).
25. Stankov, M. V. et al. Histone deacetylase inhibitors induce apoptosis in myeloid
leukemia by suppressing autophagy. Leukemia 28, 577–588 (2014).
26. Zhang, J. et al. Histone deacetylase inhibitors induce autophagy through
FOXO1-dependent pathways. Autophagy 11, 629–642 (2015).
27. Di Pompo, G. et al. Novel histone deacetylase inhibitors induce growth arrest,
apoptosis, and differentiation in sarcoma cancer stem cells. J. Med. Chem. 58,
4073–4079 (2015).
28. Bauer, S. et al. Phase I study of panobinostat and imatinib in patients with
treatment-refractory metastatic gastrointestinal stromal tumors. Br. J. Cancer
110, 1155–1162 (2014).
29. Vitfell-Rasmussen, J. et al. A phase I/II clinical trial of belinostat (PXD101) in
combination with doxorubicin in patients with soft tissue sarcomas. Sarcoma
2016, 2090271 (2016).
30. Cassier, P. A. et al. A phase II trial of panobinostat in patients with advanced
pretreated soft tissue sarcoma. A study from the French Sarcoma Group. Br. J.
Cancer 109, 909–914 (2013).
31. Furlan, A. et al. Pharmacokinetics, safety and inducible cytokine responses
during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givi-
nostat). Mol. Med. 17, 353–362 (2011).
32. Rambaldi, A. et al. A pilot study of the histone-deacetylase inhibitor givinostat
in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br.
J. Haematol. 150, 446–455 (2010).
33. Zappasodi, R. et al. Pleiotropic antitumor effects of the pan-HDAC inhibitor
ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lympho-
mas. Int. J. Cancer 135, 2034–2045 (2014).
34. Golay, J. et al. The histone deacetylase inhibitor ITF2357 has anti-leukemic
activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal
cells. Leukemia 21, 1892–1900 (2007).
35. Todoerti, K. et al. Pleiotropic anti-myeloma activity of ITF2357: inhibition of
interleukin-6 receptor signaling and repression of miR-19a and miR-19b.
Haematologica 95, 260–269 (2010).
Di Martile et al. Oncogenesis  (2018) 7:20 Page 13 of 14
Oncogenesis
36. Angeletti, F. et al. Inhibition of the autophagy pathway synergistically
potentiates the cytotoxic activity of givinostat (ITF2357) on human glio-
blastoma cancer stem cells. Front. Mol. Neurosci. 9, 107 (2016).
37. Del Bufalo, D. et al. Histone deacetylase inhibition synergistically enhances
pemetrexed cytotoxicity through induction of apoptosis and autophagy in
non-small cell lung cancer. Mol. Cancer 13, 230 (2014).
38. Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for
monitoring autophagy (3rd edition). Autophagy 12, 1–222 (2016).
39. Coomans de Brachene, A. & Demoulin, J. B. FOXO transcription
factors in cancer development and therapy. Cell. Mol. Life Sci. 73, 1159–1172
(2016).
40. Rodrigues, M., Kalinowska, W., Zielinski, C. & Sinzinger, H. Verapamil decreases
accumulation of 99Tcm-MIBI and 99Tcm-tetrofosmin in human breast
cancer and soft tissue sarcoma cell lines. Nucl. Med. Commun. 22, 645–650
(2001).
41. Pistritto, G., Trisciuoglio, D., Ceci, C., Garufi, A. & D’Orazi, G. Apoptosis as
anticancer mechanism: function and dysfunction of its modulators and tar-
geted therapeutic strategies. Aging 8, 603–619 (2016).
42. Ferraiuolo, M., Di Agostino, S., Blandino, G. & Strano, S. Oncogenic intra-p53
family member interactions in human cancers. Front. Oncol. 6, 77 (2016).
43. Koeneke, E., Witt, O. & Oehme, I. HDAC family members intertwined in the
regulation of autophagy: a druggable vulnerability in aggressive tumor enti-
ties. Cells 4, 135–168 (2015).
44. Fulda, S. & Kogel, D. Cell death by autophagy: emerging molecular
mechanisms and implications for cancer therapy. Oncogene 34, 5105–5113
(2015).
45. Schmitt-Ney, M. & Camussi, G. The PAX3-FOXO1 fusion protein present in
rhabdomyosarcoma interferes with normal FOXO activity and the TGF-beta
pathway. PLoS ONE 10, e0121474 (2015).
46. Guan, H. et al. FOXO1 inhibits osteosarcoma oncogenesis via Wnt/beta-
catenin pathway suppression. Oncogenesis 4, e166 (2015).
47. Lopez, G. et al. Combining PCI-24781, a novel histone deacetylase inhibitor,
with chemotherapy for the treatment of soft tissue sarcoma. Clin. Cancer Res.
15, 3472–3483 (2009).
48. Ragazzoni, Y. et al. The thiazole derivative CPTH6 impairs autophagy. Cell
Death Dis. 4, e524 (2013).
Di Martile et al. Oncogenesis  (2018) 7:20 Page 14 of 14
Oncogenesis
